Parkinson's Disease Therapeutics Market Size Global Report 2032

Parkinson’s Disease Therapeutics Market: Industry Perspective

The global parkinson’s disease therapeutics market size was worth around USD 3.75 billion in 2023 and is predicted to grow to around USD 5.86 billion by 2032 with a compound annual growth rate (CAGR) of roughly 5.1% between 2024 and 2032.

The report analyzes the global parkinson’s disease therapeutics market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the parkinson’s disease therapeutics industry.

Request Free Sample

Parkinson’s Disease Therapeutics Market: Overview

Parkinson’s disease (PD) is a nervous system disorder that increases in severity with time. The disease is characterized by its bradykinesia, rigidity, tremor, and postural instability. Some of the most common symptoms of Parkinson’s disease include arms, hand, or leg tremors, problems associated with balancing and walking, stiff muscles, and slow physical movements. Other symptoms include constipation, trouble in swallowing, dementia, fixed or blank expressions, and speech disabilities. However, the exact cause causing the disease is still not known, but it generally affects the patients of the older age group, i.e., mostly more than 50 years in age.

Parkinson’s Disease Therapeutics Market: Growth Factors

The global Parkinson’s disease therapeutics market is likely to be driven by the launch of prominent pipeline drugs like ND0612H, Accordion Pill, APL-130277, P2B-001, etc., increasing research and development activities for the development of novel Parkinson’s disease therapeutic drugs, and rising Parkinson’s disease incidences. The incidence rate of Parkinson’s disease increases with growing age. Additionally, the world’s population above 65 years is likely to increase from 6.8% in 2000 to almost 17% by 2050, which is a major driver for Parkinson’s disease therapeutics market growth.

Parkinson’s Disease Therapeutics Market: Segmentation

Based on drug class, the market includes dopamine agonists, catechol-o-methyltransferase (COMT) inhibitors, anticholinergic drugs, levodopa combination, monoamine oxidase B (MAO-B) inhibitors, and others.

Based on the route of administration, the market includes transdermal, oral, subcutaneous, and intestinal infusion. The oral segment held a significant share of the market in 2023 globally.

The distribution channel of the Parkinson’s disease therapeutics market is fragmented into retail pharmacy, online sales, and hospital pharmacy. The retail pharmacy segment dominated the global market in 2023 and is projected to hold a significant market share in the future.

Parkinson’s Disease Therapeutics Market: Report Scope

Parkinson’s Disease Therapeutics Market: Competitive Analysis

Some of the major players in the global parkinson’s disease therapeutics market include:

• Teva Pharmaceutical Industries
• STADA Arzneimittel
• Impax Laboratories
• Novartis
• F. Hoffmann-La Roche
• Merck & Co.
• UCB Inc.
• GlaxoSmithKline
• AbbVie
• Valeant Pharmaceuticals International

The global parkinson’s disease therapeutics market is segmented as follows;

Global Parkinson’s Disease Therapeutics Market: Drug Class Analysis

• Levodopa Combination
• Dopamine Agonists
• Monoamine Oxidase B (Mao-B) Inhibitors
• Anticholinergic Drugs
• Catechol-O-Methyltransferase (COMT) Inhibitors
• Others

Global Parkinson’s Disease Therapeutics Market: Route of Administration Analysis

• Oral
• Transdermal
• Subcutaneous
• Intestinal Infusion

Global Parkinson’s Disease Therapeutics Market: Distribution Channel Analysis

• Hospital Pharmacy
• Retail Pharmacy
• Online Sales

Global Parkinson’s Disease Therapeutics Market: Regional Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa